Novo-Nordisk A/S Newsroom

Erste Group Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating

Futu NewsOct 28 20:32

Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential

Seeking AlphaOct 24 01:29

BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $156

Futu NewsOct 17 22:31

Novo Nordisk Analyst Ratings

BenzingaOct 17 21:57

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaOct 10 23:20

Novo Nordisk Analyst Ratings

BenzingaOct 10 23:19

TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155

Futu NewsOct 8 12:32

BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating

Futu NewsOct 2 22:31

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

Barron'sOct 2 21:48

BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160

Futu NewsSep 25 19:33

BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160

Futu NewsSep 21 08:32

TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $155

Futu NewsSep 21 08:32

Novo Nordisk Analyst Ratings

BenzingaSep 20 22:04

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaSep 20 22:04

Cantor Fitzgerald Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160

Futu NewsSep 20 20:31

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

BenzingaSep 17 00:24

Novo Nordisk Analyst Ratings

BenzingaSep 17 00:23

Cantor Fitzgerald Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160

Futu NewsSep 12 04:32

BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160

Futu NewsSep 12 03:31

Novo Nordisk Analyst Ratings

BenzingaAug 20 00:27